From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

CLICK HERE FOR CME CREDIT

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Erik S.G Stroes, MD, PhD

Erik S.G Stroes, MD, PhD

Professor Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands